Generic Drug Industry to Advise Senators of Problems with Canada's Access to
Medicines Regime

TORONTO , Oct. 21 /CNW/ - Canada's generic pharmaceutical industry will appear before the Senate Banking, Trade and Commerce Committee on October 22nd to discuss problems with Canada's Access to Medicines Regime (CAMR), which aims to deliver Canadian-made generic pharmaceuticals to developing countries facing health emergencies. The Committee is reviewing Bill S-232, which would correct many of the fundamental flaws with the regime and greatly streamline the CAMR process. Generic drug maker Apotex, the first and only company to attempt to use the regime, will discuss its experience in developing and shipping a triple-combination HIV/AIDS drug to Rwanda .

    
    Date:      Thursday, October 22, 2009
    Time:      11:30 a.m. to 12:30 p.m.
    Location:  Room 9, Victoria Building 140 Wellington Street
    Webcast:   http://senparlvu.parl.gc.ca/ (BANK Meeting No. 29)

    Witnesses: Jim Keon, President, Canadian Generic Pharmaceutical
               Association
               Jack Kay, President and COO, Apotex Inc.
               Bruce Clark, Vice President, Regulatory and Medical Affairs,
               Apotex Inc.
    

For further information: Jeff Connell, Director of Public Affairs, Canadian Generic Pharmaceutical Association (CGPA), Tel: [phone], Cell: [phone], Email: [email protected], Website: www.canadiangenerics.ca